EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

Remo Panaccione  1     Anita Afzali  2     David P. Hudesman  3     Garrett Lawlor  4     Mark T. Osterman  4     Arteid Memaj  4     Miguel Regueiro  5     Subrata Ghosh  6    
1 Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Canada
2 The Ohio State University Wexner Medical Center, Columbus, United States
3 NYU Langone Health, New York, United States
4 Bristol Myers Squibb, Princeton, United States
5 Cleveland Clinic, Cleveland, United States
6 College of Medicine and Health, University College Cork, Cork, Ireland

Topic
IBD, Nurses, Primary Care

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing